Guest Editors
Prof. Keiko Yanagihara
Email: keikof@nms.ac.jp
Affiliation: Department of Breast Surgery and Oncology, Nippon Medical School Hospital, Tokyo, 113-8603, Japan
Homepage:
Research Interests: breast cancer, oncology, breast surgery
Summary
Breast cancer remains one of the most prevalent malignancies worldwide, with substantial heterogeneity across molecular subtypes and clinical behavior. Advances in targeted and precision medicine have significantly transformed therapeutic strategies, providing more individualized treatment approaches and improving patient outcomes. Topics of interest include targeted therapies against HER2, PI3K/AKT/mTOR, and other actionable pathways, immune checkpoint inhibitors, antibody–drug conjugates, and endocrine resistance mechanisms. The integration of CDK4/6 inhibitors with endocrine therapy has established a new standard of care in hormone receptor–positive disease, while immunotherapy has expanded options in triple-negative breast cancer, guided by predictive biomarkers such as PD-L1 expression. In addition, genomic and molecular profiling is increasingly applied to identify patient subgroups most likely to benefit from specific interventions, supporting biomarker-driven decision-making. Ongoing clinical trials are further refining sequencing strategies, novel combinations, and precision-based regimens. This special issue aims to showcase original research, clinical trials, and comprehensive reviews that highlight recent advances in targeted and precision medicine, with the ultimate goal of enhancing survival, reducing treatment burden, and improving quality of life for patients with breast cancer.
Keywords
breast cancer, precision oncology, targeted therapies, immunotherapy, antibody–drug conjugates, endocrine resistance, biomarkers, clinical trials
Login
Register
Submit a Paper
Propose a Special lssue